Genome-wide screen reveals Rab12 GTPase as a critical activator of Parkinson’s disease-linked LRRK2 kinase
eLife · 24.10.2023 · 12
DOI: 10.7554/elife.87098 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, online erschienen am 24.10.2023. Verfasst von Herschel S Dhekne und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Stanford University School of Medicine, Stanford, United States. Hauptthemen laut MEDLINE: Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Parkinson Disease, rab GTP-Binding Proteins. Die Arbeit wurde bisher 81-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, NIGMS NIH HHS, NIH HHS.
Abstract (Originalsprache)
Activating mutations in the leucine-rich repeat kinase 2 (LRRK2) cause Parkinson’s disease. LRRK2 phosphorylates a subset of Rab GTPases, particularly Rab10 and Rab8A, and we showed previously that these phosphoRabs play an important role in LRRK2 membrane recruitment and activation (Vides et al., 2022). To learn more about LRRK2 pathway regulation, we carried out an unbiased, CRISPR-based genome-wide screen to identify modifiers of cellular phosphoRab10 levels. A flow cytometry assay was developed to detect changes in phosphoRab10 levels in pools of mouse NIH-3T3 cells harboring unique CRISPR guide sequences. Multiple negative and positive regulators were identified; surprisingly, knockout of the Rab12 gene was especially effective in decreasing phosphoRab10 levels in multiple cell types and knockout mouse tissues. Rab-driven increases in phosphoRab10 were specific for Rab12, LRRK2-dependent and PPM1H phosphatase-reversible, and did not require Rab12 phosphorylation; they were seen with wild type and pathogenic G2019S and R1441C LRRK2. As expected for a protein that regulates LRRK2 activity, Rab12 also influenced primary cilia formation. AlphaFold modeling revealed a novel Rab12 binding site in the LRRK2 Armadillo domain, and we show that residues predicted to be essential for Rab12 interaction at this site influence phosphoRab10 and phosphoRab12 levels in a manner distinct from Rab29 activation of LRRK2. Our data show that Rab12 binding to a new site in the LRRK2 Armadillo domain activates LRRK2 kinase for Rab phosphorylation and could serve as a new therapeutic target for a novel class of LRRK2 inhibitors that do not target the kinase domain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Stanford University School of Medicine, Stanford, United States.
- Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Stanford, United States.
- MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, United Kingdom.
ORCID-Profile: Herschel S Dhekne, Francesca Tonelli, Wondwossen M Yeshaw, Claire Y Chiang, Charles Limouse, Ebsy Jaimon, Elena Purlyte, Dario R Alessi, Suzanne R Pfeffer
Förderung
- Medical Research Council
- NIGMS NIH HHS
- NIH HHS
- Aligning Science Across Parkinson’s
- Michael J. Fox Foundation for Parkinson's Research
- National Institutes of Health
- Boehringer Ingelheim
- GlaxoSmithKline
Zitieren
APA
Dhekne, H. S., Tonelli, F., Yeshaw, W. M., Chiang, C. Y., Limouse, C., Jaimon, E., Purlyte, E., Alessi, D. R., & Pfeffer, S. R. (2023). Genome-wide screen reveals Rab12 GTPase as a critical activator of Parkinson’s disease-linked LRRK2 kinase. eLife, 12. https://doi.org/10.7554/elife.87098
Vancouver
Dhekne HS, Tonelli F, Yeshaw WM, Chiang CY, Limouse C, Jaimon E, et al. Genome-wide screen reveals Rab12 GTPase as a critical activator of Parkinson’s disease-linked LRRK2 kinase. eLife. 2023;12. doi:10.7554/elife.87098
BibTeX
@article{Dhekne2023,
author = {Dhekne, Herschel S and Tonelli, Francesca and Yeshaw, Wondwossen M and Chiang, Claire Y and Limouse, Charles and Jaimon, Ebsy and Purlyte, Elena and Alessi, Dario R and Pfeffer, Suzanne R},
title = {Genome-wide screen reveals Rab12 GTPase as a critical activator of Parkinson’s disease-linked LRRK2 kinase},
journal = {eLife},
year = {2023},
volume = {12},
doi = {10.7554/elife.87098}
}
EUVIMED